Literature DB >> 1063031

Manipulation of the mitotic cycle in the treatment of acute myelogenous leukaemia.

B C Lampkin, N B McWilliams, A M Mauer, H C Flessa, D A Hake, V Fisher.   

Abstract

A priming dose of cytosine arabinoside (Ara C) was given to 16 children and five adults with acute myelogenous leukaemia (AML) to synchronize leukaemia cells in the DNA synthesis (S) phase of the mitotic cycle. An infusion of this drug, which was continued for 12 h, was started at the time of partial synchronization and was repeated every 6-12 h until the bone marrow was very hypocellular. Complete remission was achieved in 12 of 16 children and in all adults. Two of the four children went into complete remission with the addition of two doses of daunorubicin or adriamycin. These results suggest that partial synchronization of cells in the S phase results in a therapeutic advanatage in the use of Ara C for induction of a remission of AML and that manipulation of the mitotic cycle, as monitored by kinetic studies, may be helpful in planning optimal schedules for drug administration.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1063031     DOI: 10.1111/j.1365-2141.1976.tb01872.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.

Authors:  Deepa Sampath; Jorge Cortes; Zeev Estrov; Min Du; Zheng Shi; Michael Andreeff; Varsha Gandhi; William Plunkett
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

2.  Specific suppression of antibody rebound after extracorporeal immunoadsorption. I. Comparison of single versus combination chemotherapeutic agents.

Authors:  D S Terman; R Garcia-Rinaldi; B Dannemann; D Moore; C Crumb; A Tavel; R Poser
Journal:  Clin Exp Immunol       Date:  1978-10       Impact factor: 4.330

3.  Intensification of remission induction therapy for acute nonlymphocytic leukemia (ANLL). I. Response and toxicity in four different regimens.

Authors:  T Büchner; D Urbanitz; W Hiddemann; D Kamanabroo; R Meister; L Balleisen; U Delvos; E M Lagrèze; U Schmitz-Huebner; H Schulte; J van de Loo
Journal:  Blut       Date:  1979-08

4.  The relevance of cell kinetics for optimal scheduling of 1-beta-D-arabinofuranosyl cytosine and methotrexate in a slow growing acute myeloid leukemia (BNML).

Authors:  M Aglietta; P Sonneveld
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

Review 5.  Therapy for acute myeloid leukemia: intensive timing of induction chemotherapy.

Authors:  R J Wells; W G Woods; J D Buckley; R J Arceci
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.